Teva Pharmaceutical Industries Investor Presentation — February 2022

Document content

Teva Pharmaceutical Industries Ltd.

Fourth Quarter and Full Year

February 9, 2022Cautionary Note Regarding Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management ’s current beliefs and expectations and are subject

to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking

statements. Important factors that could cause or contribute to such differences include risks relating to:

•our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic product s; consolidation of our customer base and commercial alliances among our customers;

delays in launches of new generic products; the increase in the number of competitors targeting generic opportunities and seekin g U.S. market exclusivity for generic versions of significant products; our ability to

develop and commercialize biopharmaceutical products; competition for our specialty products, including AUSTEDO®, AJOVY®and COPAXONE®; our ability to achieve expected results from investments in our

product pipeline; our ability to develop and commercialize additional pharmaceutical products; and the effectiveness of our patents and other measures to protect our intellectual property rights;

•our substantial indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions ormake new investments, may result in a further downgrade of our credit ratings; and

our inability to raise debt or borrow funds in amounts or on terms that are favorable to us;

•our business and operations in general, including: uncertainty regarding the COVID -19 pandemic and the governmental and societal responses thereto; our ability to successfully execute and maintain the

activities and efforts related to the measures we have taken or may take in response to the COVID -19 pandemic and associated costs therewith; effectiveness of our optimization efforts; our ability to attract, hire

and retain highly skilled personnel; manufacturing or quality control problems; interruptions in our supply chain; disruptions o f information technology systems; breaches of our data security; variations in

intellectual property laws; challenges associated with conducting business globally, including political or economic instabil ity, major hostilities or terrorism; costs and delays resulting from the extensive

pharmaceutical regulation to which we are subject or delays in governmental processing time due to travel and work restrictions caused by the COVID -19 pandemic; the effects of reforms in healthcare regulation